Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Human erythrovirus B19 and blood transfusion – an update

Human erythrovirus B19 and blood transfusion – an update summary Erythrovirus (parvovirus) B19 (B19) is a common human pathogen. It is a non‐enveloped single‐strand DNA virus packaging its genome in small tight capsids consisting of viral VP1 and VP2 proteins. It is now accepted that B19 is a relatively quickly evolving virus having diverged in several genetic variants recently identified. The main route of B19 transmission is respiratory, with a majority of infections occurring during childhood and manifesting as erythema infectiousum. B19 can also be transmitted vertically and via blood transfusion and organ transplantation. The majority of adult populations show immunological evidence of previous exposure to B19. Although the immune response is able to clear infection and provide life‐long protection against B19, recent data suggest that in some, if not the majority, of individuals the acute phase of infection is followed by viral persistence in the blood or other tissues regardless of the host’s immunocompetence. Transmission of B19 by blood and blood products and its resistance to common viral inactivation methods raises several blood safety questions, still unanswered. The diversity of B19 strains and the ability of the virus to persist in the presence of specific antibodies raise the issue of transmissibility by transfusion not so much to immunocompetent recipients but rather to the large proportion of recipients in whom there is some degree of immunodeficiency. The ability of the virus to reactivate in immunodeficient recipients may create difficulties in differentiating between transfusion transmission and reactivation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Medicine Wiley

Human erythrovirus B19 and blood transfusion – an update

Transfusion Medicine , Volume 17 (4) – Jan 1, 2007

Loading next page...
 
/lp/wiley/human-erythrovirus-b19-and-blood-transfusion-an-update-x11zN7dz9e

References (132)

Publisher
Wiley
Copyright
Copyright © 2007 Wiley Subscription Services
ISSN
0958-7578
eISSN
1365-3148
DOI
10.1111/j.1365-3148.2007.00765.x
pmid
17680952
Publisher site
See Article on Publisher Site

Abstract

summary Erythrovirus (parvovirus) B19 (B19) is a common human pathogen. It is a non‐enveloped single‐strand DNA virus packaging its genome in small tight capsids consisting of viral VP1 and VP2 proteins. It is now accepted that B19 is a relatively quickly evolving virus having diverged in several genetic variants recently identified. The main route of B19 transmission is respiratory, with a majority of infections occurring during childhood and manifesting as erythema infectiousum. B19 can also be transmitted vertically and via blood transfusion and organ transplantation. The majority of adult populations show immunological evidence of previous exposure to B19. Although the immune response is able to clear infection and provide life‐long protection against B19, recent data suggest that in some, if not the majority, of individuals the acute phase of infection is followed by viral persistence in the blood or other tissues regardless of the host’s immunocompetence. Transmission of B19 by blood and blood products and its resistance to common viral inactivation methods raises several blood safety questions, still unanswered. The diversity of B19 strains and the ability of the virus to persist in the presence of specific antibodies raise the issue of transmissibility by transfusion not so much to immunocompetent recipients but rather to the large proportion of recipients in whom there is some degree of immunodeficiency. The ability of the virus to reactivate in immunodeficient recipients may create difficulties in differentiating between transfusion transmission and reactivation.

Journal

Transfusion MedicineWiley

Published: Jan 1, 2007

Keywords: ; ; ; ; ;

There are no references for this article.